Q-omics provides the consensus-scored TUBGCP6 profile across patient tissues and cancer cell-line models. TUBGCP6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TUBGCP6 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, TUBGCP6 protein abundance shows 27,492 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, LIHC, and PDAC as cancer lineages where TUBGCP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBGCP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBGCP6 survival associations across molecular data types. TUBGCP6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBGCP6 RNA expression–survival associations across cancer types. High TUBGCP6 expression shows unfavorable associations in ACC, KIRC and OV, but favorable associations in BLCA, ESCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TUBGCP6 RNA expression.
This table summarizes TUBGCP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 11. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TUBGCP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBGCP6 shows lower tumor expression in BRCA and higher tumor expression in LIHC, COAD, HNSC, CHOL and STAD. The LIHC box plot shows higher TUBGCP6 RNA expression in tumor versus normal tissue (log2 FC = +1.152, t-test p < 0.001).
This table shows molecular features associated with TUBGCP6 in patient tissues and cancer cell lines. In patient samples, TUBGCP6 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBGCP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
